DRD2 and cancer: Given that normalization of the tumour vasculature improves intratumoral accessibility of anti-cancer agents [70], we hypothesized that D2R agonist treatment may reduce chemotherapy-refractory SCLC progression by decreasing tumour angiogenesis within the lung tumour microenvironment, enhancing the anti-cancer effects of the chemotherapy.